ANTIBODIES TO ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS INADEQUATE RESPONDERS AND CLINICAL OUTCOMES AFTER AN ACTIVE SWITCH TO INFLIXIMAB

被引：0
|
作者：
Pool, C. [1 ]
Shankar, G. [2 ]
Schantz, A. [2 ]
Gunn, G. [2 ]
Bolce, R. [1 ]
Leirisalo-Repo, M. [3 ]
Wang, J. [2 ]
Goldman, J.
DeHoratius, R. [1 ]
Fleischmann, R. [4 ]
Decktor, D. [1 ]
机构：
[1] Janssen Serv LLC, Horsham, PA USA
[2] Janssen R&D LLC, Spring House, PA USA
[3] Helsinki U Cent Hosp, Helsinki, Finland
[4] Metroplex Clin Res Ctr, Dallas, TX USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [21] Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
    Downey, Colum
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 536 - 550
  • [22] Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
    Eng, Grith P.
    Bendtzen, Klaus
    Bliddal, Henning
    Stoltenberg, Michael
    Szkudlarek, Marcin
    Fana, Viktoria
    Lindegaard, Hanne M.
    Omerovic, Emina
    Hojgaard, Pil
    Jensen, Elmo K.
    Bouchelouche, Pierre N.
    ARTHRITIS, 2015,
  • [23] Do patients with rheumatoid arthritis demonstrate an improvement on etanercept following an inadequate response to infliximab?
    Buch, MH
    Bingham, SJ
    Bejarano, V
    White, J
    Emery, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S325 - S325
  • [24] Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure
    Wakabayashi, Hiroki
    Hasegawa, Masahiro
    Nishioka, Yosuke
    Minami, Yukari
    Nishioka, Kusuki
    Sudo, Akihiro
    CLINICAL RHEUMATOLOGY, 2013, 32 (02) : 253 - 259
  • [25] EXPERIENCE IN THE SWITCH FROM INFLIXIMAB TO ETANERCEPT, OR VICE VERSA IN RHEUMATOID ARTHRITIS PATIENTS
    Estefania, M.
    Alba, E.
    Luciana, G.
    Ana, U.
    Carlos, T.
    Sara, M.
    RHEUMATOLOGY, 2002, 41 : 93 - 94
  • [26] Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Moots, R. J.
    Xavier, Ricardo
    Mok, Chi Chiu
    Rahman, Mahboob U.
    Tsai, Wen-Chan
    Al Maini, Mustafa
    Pavelka, Karel
    Mahgoub, Ehab
    Kotak, Sameer
    Korth-Bradley, Joan
    Pedersen, Ronald
    Mele, Linda
    Shen, Qi
    Vlahos, Bonnie
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [27] Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Maid, Pablo J.
    Xavier, Ricardo
    Real, Rosa M.
    Pedersen, Ron
    Shen, Qi
    Marshall, Lisa
    Solano, Gaston
    Elena Borlenghi, Cecilia
    Pardo Hidalgo, Rodolfo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 (04) : 177 - 182
  • [28] Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al
    Francis, Serene
    Block, Joel A.
    ARTHRITIS AND RHEUMATISM, 2010, 62 (09): : 2826 - 2826
  • [29] Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
    Laas, Karin
    Peltomaa, Ritva
    Kautiainen, Hannu
    Leirisalo-Repo, Marjatta
    CLINICAL RHEUMATOLOGY, 2008, 27 (07) : 927 - 932
  • [30] Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
    Karin Laas
    Ritva Peltomaa
    Hannu Kautiainen
    Marjatta Leirisalo-Repo
    Clinical Rheumatology, 2008, 27 : 927 - 932
12345